Purpose
It is well established that empirically supported treatments reduce
depressive symptoms for the majority of adolescents; however, it is not yet
known whether these interventions lead to sustained improvements in global
functioning. The goal of this study is to assess the clinical
characteristics and trajectories of long-term psychosocial functioning among
emerging adults who have experienced adolescent-onset MDD.
Methods
Global functioning was assessed using the Clinical Global Assessment
Scale for Children (CGAS; participants ≤18 years old), the Global
Assessment of Functioning (GAF; participants ≥ 19 years old) and the
Health of the Nation Outcome Scales for Adolescents (HONOSCA) among 196
adolescents who elected to complete 3.5 years of naturalistic follow-up
subsequent to their participation in the Treatment for Adolescents with
Depression Study (TADS). TADS examined the efficacy of cognitive behavior
therapy (CBT), fluoxetine (FLX), and the combination of CBT and FLX (COMB)
over 36 weeks. Mixed-effects regression models were used to identify
trajectories and clinical predictors of functioning over the naturalistic
follow-up.
Results
Global functioning and achievement of developmental milestones
(college, employment) improved over the course of follow-up for the majority
of adolescents. Depressive relapse, initial randomization to the placebo
(PBO) group, and the presence of multiple psychiatric comorbidities
conferred risk for relatively poorer functioning.
Conclusions
Functioning generally improves among the majority of adolescents who
have received empirically supported treatments. However, the presence of
recurrent MDD and multiple psychiatric comorbidities is associated with
poorer functioning trajectories, offering targets for maintenance treatment
or secondary prevention.